Antifolate C2 is used for the research of non-squamous non-small cell lung cancer (NS-NSCLC), particularly in patients who respond poorly to Pemetrexed; it inhibits tumor cell proliferation by selectively targeting the proton-coupled folate transporter (PCFT) and blocking de novo purine nucleotide biosynthesis through inhibition of glycinamide ribonucleotide formyltransferase (GARFTase).